|
Maya's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: Immunome seeks EU approval for a desmoid tumor treatment, Sanofi hunts late-stage drug assets, and HanchorBio advances HCB303 into regional Phase 1 development.
The top 10 stories from Fri Oct 30, 2026 07:01 AM to Mon Nov 2, 2026 06:57 AM
Generated November 2, 2026 at 6:57 AM
|
|
|
#1 US FDA’s November Calendar Pairs Big Oncology Bets With Potential Rare Disease Firsts Published 2026-10-30 The FDA’s November user-fee calendar includes 14 novel agents, spanning oncology candidates and potential first treatments for rare diseases. Covered by: insights.citeline.com, biocentury.com |
#2 Beyond Conventional Anti-TIGIT: HanchorBio Secures Taiwan TFDA Approval for HCB303 Following U.S. FDA Clearance Published 2026-10-30 HanchorBio received Taiwan TFDA approval for HCB303 after U.S. FDA clearance, advancing the trispecific TIGIT-Fc ligand trap toward multi-regional Phase 1 development. Covered by: prnewswire.com |
#3 Once undruggable, the Wnt/B-catenin pathway shows increasing promise Published 2026-10-30 Early clinical data from several companies suggest the Wnt/β-catenin pathway may offer a treatment target across multiple cancer types. Covered by: biospace.com |
#4 Anthropic’s one-person biotech buy; Jake Van Naarden’s dealmaking strategy; and more Published 2026-10-31 Endpoints Weekly’s Halloween edition covers Anthropic’s one-person biotech acquisition and Jake Van Naarden’s dealmaking strategy. Covered by: endpoints.news |
#5 This week in charts: ESMO’s winners and losers Published 2026-10-30 BioPharma Dive charts Wall Street’s response to three closely watched presentations at the European Society for Medical Oncology meeting. Covered by: biopharmadive.com |
#6 Quick Listen: Scrip’s Five Must-Know Things Published 2026-11-02 Scrip’s latest episode covers the US COINS Act, GSK’s oncology turnaround, Lilly’s KRAS efforts, ris-rez in osteosarcoma, and a Genmab Phase III result. Covered by: insights.citeline.com |
#7 Big Pharma, Domestic Firms Feel India’s Cancer Drug Trade Margin Cap Squeeze Differently Published 2026-10-30 India’s cancer drug trade-margin cap has lowered prices, with multinational and domestic pharmaceutical companies experiencing different effects. Covered by: insights.citeline.com |
#8 New EU Filings Published 2026-10-30 Immunome has filed varegacestat, a treatment for adults with desmoid tumors, with the European Medicines Agency for potential EU marketing approval. Covered by: insights.citeline.com |
#9 Sanofi On Lookout For Late-Stage Assets As Q3 Sales Climb Published 2026-10-30 Sanofi is seeking late-stage drug assets as its third-quarter sales rise. Covered by: insights.citeline.com |
#10 Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials Published 2026-10-30 Gilead Sciences placed a partial clinical hold on two trials of its CAR-T therapy KITE-753 for diffuse large B-cell lymphoma. Covered by: fiercebiotech.com, endpoints.news |
